EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Characteristics and outcome of patients with brain metastases from colorectal cancer

Robin van den Borg, Sophie L Kuhlmann, Dieta Brandsma iD, Tineke E Buffart iD

Neuro-Oncology Practice · 09.10.2025 · 12 (5) · 873-883

DOI: 10.1093/nop/npaf040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 17.04.2025. Verfasst von Robin van den Borg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite a generally poor prognosis of patients with brain metastases of colorectal cancer (CRC-BM), local treatment of BM might be beneficial in selected patients. The aim of this study was to characterize patient and clinicopathological characteristics of CRC-BM and to identify patients who benefit most from local treatment of CRC-BM.

Methods

In this retrospective cohort study, clinicopathological characteristics, including treatment response and survival, were collected from 100 patients who were treated for CRC-BM at the Netherlands Cancer Institute between 2001 and 2021. All analyses were performed using SPSS.

Results

Median overall survival (OS) from CRC diagnosis and diagnosis of BM was 47.3 and 5.2 months, respectively. Median brain metastasis-free interval (BMFI) was 39.0 months. Median OS of patients with metachronous extracranial metastases (ECM) and subsequent BM was 5.7 months compared to 2.8 months in patients with synchronous ECM and subsequent BM (P = .08). In the latter group, the diameter of BM and liver metastases negatively influenced survival. OS of patients with CRC-BM improved over time (9.0 vs 4.0 months in 2016-2021 vs 2001-2015, respectively (P = .002)) and was better in patients able to receive systemic therapy after diagnosis of CRC-BM compared to patients who did not (19.4 months vs 4.7 months; P = .005).

Conclusions

Although the development of BM in patients with CRC is a late event resulting in a poor prognosis, outcome improved over time. OS was significantly longer in patients who still have systemic treatment options. This can be taken into account in the decision for local treatment of patients with CRC-BM.

Schlagwörter

Stichwörter der Autor:innen

brain metastasiscolorectal cancersurvivaltreatment

Autor:innen und Institutionen

  • Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Dieta Brandsma, Tineke E Buffart

Zitieren

APA

van den Borg, R., Kuhlmann, S. L., Brandsma, D., & Buffart, T. E. (2025). Characteristics and outcome of patients with brain metastases from colorectal cancer. Neuro-Oncology Practice, 12(5), 873-883. https://doi.org/10.1093/nop/npaf040

Vancouver

van den Borg R, Kuhlmann SL, Brandsma D, Buffart TE. Characteristics and outcome of patients with brain metastases from colorectal cancer. Neuro-Oncology Practice. 2025;12(5):873-883. doi:10.1093/nop/npaf040

BibTeX
@article{vandenBorg2025,
  author = {van den Borg, Robin and Kuhlmann, Sophie L and Brandsma, Dieta and Buffart, Tineke E},
  title = {Characteristics and outcome of patients with brain metastases from colorectal cancer},
  journal = {Neuro-Oncology Practice},
  year = {2025},
  volume = {12},
  number = {5},
  pages = {873--883},
  doi = {10.1093/nop/npaf040}
}
Kostenlos starten →